AZD-2115(AZD-2115) - 药物靶点：M3 receptor x β2-adrenergic receptor_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

M3 receptor x β2-adrenergic receptor

作用机制

M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂)

治疗领域

呼吸系统疾病

在研适应症-

非在研适应症

气道病变慢性阻塞性肺疾病

原研机构

AstraZeneca PLC

在研机构-

非在研机构

AstraZeneca PLC

Pearl Therapeutics, Inc.

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

5

项与 AZD-2115 相关的临床试验

NCT03097380

/ Completed临床1期

An Open-label Positron Emission Tomography Phase I Study to Determine Muscarinic Receptor Occupancy in the Lungs in Healthy Volunteers After Inhalation of Single Dose of Tiotropium or AZD2115.

An open-label study using positionemissiontomography (PET) to explore the binding of AZD2115 and Tiotropium to muscarinic receptors in the lungs in healthy volunteers after inhalation.

开始日期2017-04-26

申办/合作机构

AstraZeneca PLC

NCT02109406

/ Completed临床2期

A Randomized, Double Blind, Chronic Dosing (14 Days), Three Period, Placebo Controlled, Cross Over, Multi Center Study to Assess Efficacy and Safety of Two Dose Levels of AZD2115 MDI in Subjects With Moderate to Severe COPD

This is a phase IIa dose-ranging, randomized, double-blind, chronic-dosing (14 Days), three-period, placebo-controlled, multi-center, cross-over study to assess the efficacy and safety of two dose levels of a dual pharmacology molecule with the combined properties of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA); (AZD2115) delivered by a metered-dose inhaler (MDI) in subjects with moderate to severe chronic obstructive pulmonary disease (COPD).

开始日期2014-05-01

申办/合作机构

Pearl Therapeutics, Inc.

NCT01498081

/ Completed临床2期

A Randomised, Double-blind, Placebo and Active Controlled, Multi-centre, 6 Way Cross-over, Single-dose Phase IIa Study to Investigate the Local and Systemic Effects of 3 Different Doses of Inhaled AZD2115 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

This study in COPD patients will investigate the bronchodilatory effect of AZD2115. AZD2115 will be tested versus placebo and active comparators. The safety and tolerability of AZD2115 including investigations of clinically relevant systemically mediated effects will also be investigated.

开始日期2012-03-01

申办/合作机构

AstraZeneca PLC

100 项与 AZD-2115 相关的临床结果

登录后查看更多信息

100 项与 AZD-2115 相关的转化医学

登录后查看更多信息

100 项与 AZD-2115 相关的专利（医药）

登录后查看更多信息

1

项与 AZD-2115 相关的文献（医药）

2012-11-01·Expert Opinion on Therapeutic Patents2区 · 医学

Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115?

2区 · 医学

Article

作者: Norman, Peter

These two patent applications each claim combination formulations comprising a single dual-acting muscarinic antagonist/beta 2 agonist (MABA), as a free base or salt, with a second class of drug and the use of these formulations for the treatment of asthma and COPD. The two specified compounds are close analogues of each other and were originally disclosed in the same patent application. They are, respectively, 3-(2-chloro-3-((4-(2-ethylthiazole-4-carbonyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)methyl)phenethoxy)-N-cyclopentyl-N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b]{1,4] oxazin-8-yl)ethylamino)ethyl)propanamide and N-butyl-N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][l,4]oxazin-8-yl)ethylamino)ethyl)-3-(3-(2-(4-(2-isopropylthiazole-4-carbonyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenethoxy)propanamide.

100 项与 AZD-2115 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性阻塞性肺疾病	临床2期	瑞典	AstraZeneca PLC	2012-03-01
慢性阻塞性肺疾病	临床2期	波兰	AstraZeneca PLC	2012-03-01
气道病变	临床2期	英国	AstraZeneca PLC	2011-01-01